Form 4: Moderna Executive Reports Stock Transaction
Insider Transaction (Form 4)
Shannon Thyme Klinger, Chief Legal Officer of Moderna, Inc., reported multiple transactions in common stock on September 4, 2026.
Summary
- Option exercise/conversion: acquired 11,797 Common Stock on September 4, 2026; holds 87,044 after (Direct).
- Tax/exercise-price withholding: disposed of 5,704 Common Stock at $148.87 ($849,154) on September 4, 2026; holds 81,340 after (Direct).
- Option exercise/conversion: disposed of 11,797 Restricted Stock Units on September 4, 2026; holds 106,179 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Shannon Thyme Klinger — Officer (Chief Legal Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-04 | Option exercise/conversion | Common Stock | 11,797 | — | — | 87,044 |
| 2026-09-04 | Tax/exercise-price withholding | Common Stock | 5,704 | $149 | $849.2K | 81,340 |
| 2026-09-04 | Option exercise/conversion | Restricted Stock Units | 11,797 | — | — | 106,179 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-04 | Option exercise/conversion (11,797 shares) |
| 2026-09-04 | Tax/exercise-price withholding (5,704 shares) |
| 2026-09-04 | Option exercise/conversion (11,797 shares) |
Keywords
insider transaction, Form 4, MRNA, Moderna, Inc., neutral, Shannon Thyme Klinger
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.